Acute kidney injury (AKI) post-cardiac surgeries happens as a prompt deterioration in
renal function subsequent to cardiac surgery including cardiopulmonary bypass graft surgery
(CABG). This study is aimed to evaluate the effect of intraoperative dexmedetomidine on renal
function in patients undergoing CABG by using cardiopulmonary bypass (CPB). Methods. This
Double-blinded randomized clinical trial study was performed on 58 patients who were
candidates for CABG in Namazi Hospital of Shiraz. In the dexmedetomidine group,
dexmedetomidine infusion at a dose of 0.5 μg/kg/h without a loading dose, and in the control
group placebo was initiated. After the end of surgery and ICU admission and on days 2 and 3
postoperatively, serum BUN, Cr, and eGFR levels, also urine output, Inotrope usage, and
packed red blood cells (PRBC) consumption were recorded. SPSS software 24 was used for
data analysis. Results. No significant differences were observed in any of the steps in serum
creatinine levels between the two groups (P > 0.05). A significant difference in serum BUN
levels was observed between the two groups except for the third day (P <0.05). Heterogeneity
was seen in preoperative BUN in the two groups. There was no significant difference between
the mean of eGFR in the dexmedetomidine and control groups over time (P >0.05). There was a
significant difference between the mean urine output in the two groups only on the second day
(P = 0.04). There was no significant difference in PRBC intake and inotrope usage between the
two groups (P > 0.05). Conclusion. The findings of this study indicate that dexmedetomidine
does not affect the renal function of patients undergoing coronary artery bypass graft surgery.
According to the findings, dexmedetomidine can increase the urine output of patients during
surgery. However, it has no positive effect on the postoperative period.